Stayble Therapeutics AB

Equities

STABL

SE0013513652

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 16:23:13 17/05/2024 BST			5-day change	1st Jan Change
0.2495 ^SEK	-5.31%		-1.77%	-17.66%

02-20	Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
2023	Stayble Therapeutics Announces New Analyses of Phase IIb Study Strengthen Disc Herniation Project	CI

Stayble Therapeutics AB Elects Ulf Björklund as Chairman

June 03, 2021 at 08:14 am

Stayble Therapeutics AB (publ) announced that Ulf Björklund was elected Chairman of the Board. Björklund has extensive experience from research, development and commercialisation in the pharmaceutical industry as well as board assignments. BioStock reached out to Björklund to get his expectations for his new assignment as Chairman of Stayble Therapeutics.

Latest news about Stayble Therapeutics AB

Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-20	CI
Stayble Therapeutics Announces New Analyses of Phase IIb Study Strengthen Disc Herniation Project	12-18	CI
Stayble Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Toleranzia Appoints Successor to Outgoing CFO	16/10/23	MT
Stayble Therapeutics Terminates Liquidity Provider Agreement	06/09/23	MT
Stayble Enters the First Patient in Herniated Disc Study	04/09/23	CI
Stayable Therapeutics Enrols First Patient for Herniated Discs Trial	28/08/23	MT
Stayble Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	22/08/23	CI
Certain Shares of Stayble Therapeutics AB are subject to a Lock-Up Agreement Ending on 22-AUG-2023.	21/08/23	CI
Stayble Therapeutics Phase IIb Study Nears the Final Line	24/07/23	CI
Stayble Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23/05/23	CI
Sweden's Stayble Therapeutics Appoints Chief Medical Officer	19/04/23	MT
Stayble Therapeutics AB Adds Disc Herniation to the Pipeline - Study Approved	07/03/23	CI
Stayble Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2022	21/02/23	CI
Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	21/02/23	CI
Stayble Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/11/22	CI
Stayble Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/08/22	CI
Stayble Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2022	17/05/22	CI
Stayble Therapeutics to Continue Clinical Trial of Degenerative Disc Disease Drug in Russia; Shares Up 7%	14/03/22	MT
Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22/02/22	CI
Stayble Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	18/11/21	CI
Stayble Therapeutics Presents Interim Results from the Phase IIb Study with STA363 Demonstrating Good Safety and Tolerability	10/11/21	CI
Stayble Therapeutics AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021	16/08/21	CI
Stayble Therapeutics AB Elects Ulf Björklund as Chairman	03/06/21	CI
Stayble Therapeutics AB Announces Appointment of Sara Richardson in the New Role of CMC and Regululatory Affairs	04/05/21	CI

Chart Stayble Therapeutics AB

Duration

Period

More charts

Company Profile

Stayble Therapeutics AB is a Sweden-based life science company developing an injectable treatment STA363 against chronic low back pain triggered by disc degeneration. The solutions are offered to the patients whose back pain persists after physiotherapy and drugs. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. Main focus of the Company is to develop STA363 as a new way of treatment for patients suffering from chronic disc-related low back pain. STA363 focuses on the two primary causes of pain in degenerative disc disease: leakage of inflammatory substances and disc instability. The mechanism of action of the treatment is to stabilize the disk segment and eliminate the possibility of disk leakage.

Sector

Biotechnology & Medical Research

Calendar

19/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
STAYBLE THERAPEUTICS AB	-17.66%	739K
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
BIONTECH SE	-14.15%	21.84B
ARGENX SE	-1.05%	21.96B
GENMAB A/S	-5.29%	19.21B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
BEIGENE, LTD.	-4.16%	18.08B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs